137945-48-3Relevant articles and documents
Synthetic Nonpsychotropic Cannabinoids with Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities
Burstein, Sumner H.,Audette, Charlene A.,Breuer, Aviva,Devane, William A.,Colodner, Sharona,et al.
, p. 3135 - 3141 (1992)
Two strategies for the design of therapeutically useful cannabinoids have been combined to produce compounds with greatly increased antiinflammatory activity and with a low potential for adverse side effects.Enantiomeric cannabinoids with a carboxylic acid group at position 7 and with an elongated and branched alkyl sidechain at position 5' have been synthesized and tested for antiinflammatory activity.They were effective when given orally at doses of 10 μg/kg in reducing paw edema in mice that had been induced by either arachidonic acid or platelet activating factor.Leukocyte adhesion to culture dishes was also reduced in peritoneal cells from mice in which the cannabinoids were orally administered in the same dose range as for the paw edema tests.Antinociception could be observed in the mouse hot plate assay; however, little stereochemical preference was seen in contrast to the above tests where the 3R,4R compounds are more active than the 3S,4S enantiomers.Finally, in agreement with earlier reports on the naturally occurring pentyl side chain acids, the synthetic acids showed little activity in producing catalepsy in the mouse, suggesting that they would be nonpsychotropic in humans.
METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL
-
Page/Page column 35-36, (2019/05/10)
The invention provides methods and compositions relating to an ultrapure formulation of 5-(1,1-dimethylheptyl)-resorcinol (ultrapure DMHR). The invention features methods for making ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities). The invention also features methods of making cannabinoids, such as (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid (ajulemic acid), using ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities) in the resulting cannabinoid preparation.
ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS
-
Page/Page column title page; 6; figure 1, (2008/06/13)
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, (3R,4R)-Δ8-THC-11-oic acids, for treating or preventing nausea and relieving symptoms thereof.